IsoPlexis (NASDAQ:ISO) Issues Quarterly Earnings Results

IsoPlexis (NASDAQ:ISOGet Rating) released its earnings results on Wednesday. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.15), MarketWatch Earnings reports. IsoPlexis updated its FY 2022 guidance to EPS.

ISO stock opened at $2.07 on Friday. IsoPlexis has a 1 year low of $1.62 and a 1 year high of $16.95. The company has a quick ratio of 9.88, a current ratio of 11.67 and a debt-to-equity ratio of 0.22. The stock’s 50 day moving average price is $3.08 and its 200 day moving average price is $6.88.

A number of hedge funds have recently bought and sold shares of the stock. Citigroup Inc. purchased a new stake in IsoPlexis in the 4th quarter valued at approximately $36,000. California State Teachers Retirement System purchased a new position in shares of IsoPlexis during the 4th quarter worth $43,000. Deutsche Bank AG acquired a new stake in shares of IsoPlexis during the fourth quarter worth $47,000. Wells Fargo & Company MN purchased a new stake in shares of IsoPlexis in the fourth quarter valued at $48,000. Finally, JPMorgan Chase & Co. purchased a new stake in shares of IsoPlexis in the fourth quarter valued at $51,000. 76.49% of the stock is currently owned by hedge funds and other institutional investors.

ISO has been the topic of a number of research reports. SVB Leerink lowered their price target on IsoPlexis from $20.00 to $15.00 and set an “outperform” rating on the stock in a report on Thursday, January 27th. Morgan Stanley lowered their price target on IsoPlexis from $17.00 to $12.00 and set an “overweight” rating on the stock in a report on Tuesday, February 15th. Finally, Zacks Investment Research cut IsoPlexis from a “buy” rating to a “hold” rating in a report on Thursday, May 5th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $13.38.

About IsoPlexis (Get Rating)

IsoPlexis Corporation, a life sciences company, provides solutions for the development of curative medicines and personalized therapeutics in the United States, Canada, the United Kingdom, Belgium, France, the Czech Republic, Spain, Germany, Sweden, Italy, Israel, Switzerland, China and Taiwan, Singapore, Japan, Australia, and Korea.

Read More

Receive News & Ratings for IsoPlexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IsoPlexis and related companies with MarketBeat.com's FREE daily email newsletter.